腺苷对大鼠心肌缺血再灌注心律失常的影响  

Effect of adenosine on the arrhythmias induced by ischemia and reperfusion in rat

作　　者：赵正航[1] 臧伟进[1] 张风杰[1] 田田[1] 于晓江[1] 臧益民[2] 

机构地区：[1]西安交通大学医学院药理学教研室,陕西西安710061 [2]第四军医大学生理学教研室

出　　处：《心脏杂志》2001年第4期251-253,共3页Chinese Heart Journal

基　　金：国家自然科学基金资助项目 (No.3 9870 3 3 4 ;No.3 9970 2 73 )

摘　　要：目的 :研究腺苷对大鼠心肌缺血再灌注 (I/ R)致心律失常的影响以及与 ATP敏感性钾通道 (KATP)的关系。方法 :采用结扎大鼠左冠状动脉前降支造成缺血 10 min,然后再灌注 15 m in,诱发室性心律失常。在心肌缺血前分别给予腺苷 (2 ,6 mg/ kg)及 KATP阻断剂格列本脲 (Glib,7.5 mg/ kg)。结果 :1与对照组相比 ,腺苷 2 ,6 m g/ kg两剂量组可明显减少 I/ R室颤的发生率 (P<0 .0 1) ,降低心律失常评分分值 (P<0 .0 1) ,能明显降低磷酸肌酸激酶 (CPK )和乳酸脱氢酶 (L DH)活性 (P<0 .0 1)。 2 Glib阻断 KATP后 ,诱发出严重的室性心律失常 ,且 CPK,L DH值均显著高于对照组 (P<0 .0 1)。 3腺苷 6 mg/ kg在 Glib阻断 KATP后 ,亦可降低室性心律失常分值 ,降低 CPK,L DH水平 ,同Glib组相比较 ,P<0 .0 1或 P<0 .0 5。结论 :腺苷对大鼠 I/ R心肌损伤有明显的保护作用 ,而AIM: To study the protective effects of adenosone (Ado) on ischemic and reperfusive arrhythmias in rat and to probe the role of K ATP in its effects. METHODS: Left anterior descending artery of the rats were ligated with ischemia for 10 min, and then relaxed to be reperfused for 15 min to observe the effects of Ado and Glibenclamide (Glib). RESULTS: ①Compared with control group, the two dose groups of intravenous Ado (2, 6 mg/kg) decreased significantly the incidence of ventricular fibrillation (VF) and arrhythmia scores ( P <0.01), and decreased the serum creatine phosphokinase (CPK) and lactate dehydrogenese (LDH) ( P <0.01). ②Glib orally inhibited the ATP sensitive potassium current (K ATP ), induced more sever ventricular arrhythmia, and significantly increased the serum level of CPK and LDH compared with control ( P <0 01). ③ The antiarrhythmia effects of the small dose of Ado (2 mg/kg) were reversed by Glib, but the large dose (6 mg/kg) remained partially the protective effect on the ischemia and reperfusion injury in rats. CONCLUSION: Ado had significantly protective effects on the ischemia and reperfusion injury in rats, and the activation of K ATP might be involved in its mechanism.

关 键 词：腺苷 缺血再灌注 抗心律失常 ATP敏感性钾通道 

分 类 号：R542.2[医药卫生—心血管疾病]